Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease

NCT05269173 | Completed Phase 2 DMC

• 1 other identifier: HJG- MHHZHTP-XJWWEYY
• Study Type: interventional
• Target: 240
• Locations: 1 country
• Sites: 19

Brief Summary

In clinical trials of preclinical pharmacodynamic studies, Flos Gossypii Flavonoids Tablet has been proved to significantly improve the learning and memory ability of Alzheimer's disease model. Phase I clinical tolerance test is to observe the human body's tolerance to Flos Gossypii Flavonoids Tablet, and provide a basis for the formulation of safe and reasonable dosing regimens for phase II clinical trials. Therefore, a Phase II clinical trial is now being conducted to explore the efficacy and safety of the Flos Gossypii Flavonoids Tablet in the treatment of mild to moderate Alzheimer's disease (marinus sea deficiency/brain collateral stasis syndrome). In this study, the researchers will use a multicenter, randomized, double-blind, placebo-controlled parallel method to recruit AD patients to confirm the efficacy and safety of Flos Gossypii Flavonoids Tablet. Confirmation of drug efficacy will be observed through changes in AD patients' general cognitive and different cognitive domain functions, daily living activities, and symptom severities.

Conditions

Alzheimer Disease

Keywords

medullary sea deficiency; brain collateral stasis syndrome

Outcome Measures

Primary Outcomes (1)

• Alzheimer's Disease Assessment Scale-Cognitive section(ADAS-cog/11)

  Differences between the low-dose and high-dose groups in changes in ADAS cog/11 scores (relative to baseline) at weeks 13 and 26 were compared with the placebo group. The ADAS-cog/11 measures 11 items: word recall, commands, constructional praxis, naming objects or fingers, ideational praxis, orientation, word recognition, remembering word recognition test instructions, spoken language ability, word-finding difficulty and comprehension. The total score ranges from 0 to 70, with lower scores representing milder disease.

  Change from baseline in ADAS-cog scores at Week 26

Secondary Outcomes (6)

• Mini-mental State Examination (MMSE)

  Change from baseline in MMSE scores at Week 26

• Alzheimer's Disease Co-operative Study Activities of Daily Living (ADCS-ADL)

  Change from baseline in ADCS-ADL scores at Week 26

• Clinician Interview Based Impression of Severity (CIBIC-plus)

  Change from baseline in CIBIC-plus scores at Week 26

• Neuropsychiatric Inventory (NPI)

  Change from baseline the scores of 12 behavioral domains in NPI at Week 26.

• Neuropsychiatric Inventory (NPI)

  Change from baseline in Caregiver Stress Score on the NPI Scale at Week 26

Study Arms (3)

Active group(low dose group)

ACTIVE COMPARATOR

Take 5 tablets each time (including 3 tablets of study drug and 2 tablets of placebo), 3 times a day, a total of 2.7g per day. Take it with warm water half an hour before meals.

Drug: Flos gossypii flavonoids tablet

Active group(high dose group)

ACTIVE COMPARATOR

Take 5 tablets of the study drug each time, 3 times a day, a total of 4.5g per day. Take it with warm water half an hour before meals.

Drug: Flos gossypii flavonoids tablet

Control group

PLACEBO COMPARATOR

Take 5 tablets of the control drug (placebo) each time, 3 times a day, 4.5g a day. Take it with warm water half an hour before meals.

Drug: Flos gossypii flavonoids tablet

Interventions

Flos gossypii flavonoids tablet DRUG

The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.

Active group(high dose group); Active group(low dose group); Control group

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 50 to 85 years old (including 50 and 85 years old), male or female;
• Meet the diagnostic criteria of "likely ad dementia" of the National Institute on aging Alzheimer's disease association (NIA-AA) (2011);
• The subjects are primary school graduates / graduates and above, and have the ability to complete the cognitive ability test and other tests specified in the program;
• Memory loss lasted for at least 6 months and tended to worsen gradually;
• Subjects with mild or moderate illness: 11 ≤ MMSE ≤ 26;
• Total score of Clinical Dementia Rating Scale (CDR):
• Mild dementia: CDR = 1.0; Moderate dementia: CDR = 2.0;
• The total score of Hachinski scale(HIS) ≤ 4;
• The total score of Hamilton Depression Scale (HAMD 17 item version) is ≤ 10;
• There was no obvious positive sign in nervous system examination;
• Coronal scanning of head MRI in screening stage: the MTA grade of medial temporal lobe atrophy visual assessment scale is grade 2 or higher, and the signal changes of T2 FLAIR sequence in coronal position of hippocampus. If the subject can provide the head MRI film that meets the requirements within 1 month before screening, it can be used as the basis for enrollment without repeated shooting; If the researcher cannot judge whether the subject's condition has changed, the coronal MRI scan of the head before enrollment can be added;
• The subjects should have stable and reliable caregivers, who will take care of them at least 3 days a week and at least 2 hours a day. The caregivers will accompany the subjects to participate in the whole process of the study. Caregivers must accompany the subjects to the study visit and assist the investigator in completing the Neuropsychiatric Inventory (NPI), Alzheimer's Disease Collaborative Study-Ability of Daily Living Scale (ADCS-ADL), and Clinician Interview Based Impression of Severity (CIBIC -plus), and other scale scores;
• Agree to participate and sign the informed consent form by the legal guardian. Due to the subject's limited cognitive ability and other reasons, the subject's signature is allowed to be left blank, and the reason is explained. In addition, the legal guardian shall sign the reason statement, and the legal guardian shall sign the informed consent;
• Meet the criteria the traditional Chinese medicine of AD which is characterized by the syndrome of insufficient sea of marrow/cerebral collateral stasis. According to the Dementia Syndrome Classification Scale (SDSD), one of the syndromes of insufficient sea of marrow/cerebral collateral stasis can be met.

You may not qualify if:

• During screening, MRI examination showed significant focal lesions, fulfilling one of the following conditions:
• ① There were more than 2 infarcts with diameter \> 2 cm at any site;
• ② MRI examination showed that there were infarcts with arbitrary diameter in key parts (such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, angular gyrus, cortex and other subcortical gray matter nuclei);
• ③ Fazekas scale grade of white matter lesions \> 2;
• ④ There are other imaging evidences that do not support mild and moderate AD;
• Dementia caused by other reasons: vascular dementia, central nervous system infection, Creutzfeldt Jakob disease, Huntington's disease, Parkinson's disease, Lewy body dementia, traumatic dementia, other physical and chemical factors (such as drug poisoning, alcoholism, carbon monoxide poisoning, etc.), important physical diseases (such as hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space occupying lesions (such as subdural hematoma, brain tumor), endocrine disorders (such as thyroid disease, parathyroid disease), and vitamin B12, folic acid deficiency or any other known cause;
• Have suffered from central nervous system diseases (including stroke, optic neuromyelitis, epilepsy, etc.);
• Subjects who were diagnosed with psychiatric disorders according to DSM-V criteria, including schizophrenia or other mental diseases, bipolar disorder, severe depression or delirium;
• Abnormal laboratory indexes: liver function (ALT and AST) exceeded 1.5×ULN, renal function (CR) exceeded 1.5×ULN, and creatine kinase exceeded 2×ULN;
• Within 1 month of the screening visit, the subject has new or ongoing unstable or serious heart, lung, liver, kidney and hematopoietic diseases according to the judgment of the researcher, and does not meet the conditions for clinical research;
• Clinically, people with significant allergic reaction history, especially drug allergy history, or known allergy to this product and its excipients;
• Dyspepsia, esophageal reflux, gastric bleeding or peptic ulcer disease, frequent heartburn (≥ once a week) or any surgical operation that may affect drug absorption (such as partial / total gastrectomy, partial / total small bowel resection and cholecystectomy) within 6 months before screening;
• Alcohol or drug abusers;
• Human immunodeficiency virus antibody (ant HIV) and Treponema pallidum antibody (ant TP) are positive;
• Those who are currently using and cannot stop using drugs for Alzheimer's disease;

Sponsors & Collaborators

• Capital Medical University: lead
• Xinjiang Uygur Pharmaceutical Co., Ltd.: collaborator

Study Sites (19)

Hefei Second People's Hospital

Hefei, Anhui, 230012, China

Location

Lu'an Hospital of traditional Chinese Medicine

Lu'an, Anhui, 237005, China

Location

Xuanwu Hospital of Capital Medical University

Beijing, Beijing Municipality, 100053, China

Location

Oriental Hospital of Beijing University of traditional Chinese Medicine

Beijing, Beijing Municipality, 100078, China

Location

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400042, China

Location

Sun Yat Sen Memorial Hospital of Sun Yat sen University

Guangzhou, Guangdong, 510289, China

Location

Affiliated Hospital of Chengde Medical College

Chengde, Hebei, 067020, China

Location

Daqing People's Hospital

Daqing, Heilongjiang, 163711, China

Location

Luoyang First Hospital of traditional Chinese Medicine

Luoyang, Henan, 471099, China

Location

Jiangsu Hospital of traditional Chinese Medicine

Nanyang, Jiangsu, 210004, China

Location

Taizhou Hospital of traditional Chinese Medicine

Taizhou, Jiangsu, 225399, China

Location

Wuxi Second People's Hospital

Wuxi, Jiangsu, 214001, China

Location

Yangzhou First People's Hospital

Yangzhou, Jiangsu, 225007, China

Location

PLA Northern Theater Air Force Hospital

Shenyang, Liaoning, 110092, China

Location

The First Hospital of Shanxi Medical University

Taiyuan, Shanxi, 030001, China

Location

Shanxi Hospital of traditional Chinese Medicine

Xi’an, Shanxi, 710003, China

Location

Xi'an High Tech Hospital

Xi’an, Shanxi, 710077, China

Location

Xidian Group Hospital

Xi’an, Shanxi, 710077, China

Location

Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, 646000, China

Location

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director and Professor

Study Record Dates

• First Submitted: February 25, 2022
• First Posted: March 7, 2022
• Study Start: October 29, 2020
• Primary Completion: August 13, 2024
• Study Completion: November 5, 2024
• Last Updated: November 12, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (19)